Stocktoria
Heartflow, Inc. HTFL
Heartflow, Inc. (HTFL) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $176.0M at a -66.3% net margin.
Beneish M-score: -2.54 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | Freedom Capital Markets | Buy (init) |
| 2026-05-15 | Canaccord Genuity | Buy (main) |
| 2026-05-15 | Wells Fargo | Overweight (main) |
| 2026-05-04 | William Blair | Outperform (init) |
| 2026-03-19 | JP Morgan | Overweight (main) |
| 2026-03-19 | Canaccord Genuity | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.495 |
| Retained earnings / assets | -3.026 |
| EBIT / assets | -0.178 |
| Equity / liabilities | 5.113 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HTFL | Heartflow, Inc. | 4/9 | -2.45 | — | +39.9% |
| SIBN | SI-BONE, Inc. | 6/9 | 1.52 | — | +20.2% |
| STIM | Neuronetics, Inc. | 4/9 | -10.38 | — | +99.2% |
| INFU | InfuSystem Holdings, Inc | 8/9 | 1.27 | 30.1 | +6.4% |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | 2/9 | -1.79 | — | +1.6% |
| XTNT | Xtant Medical Holdings, Inc. | 8/9 | -3.66 | 12.7 | +14.2% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
About Heartflow, Inc.
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
FAQ
Is HTFL financially healthy?
Heartflow, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does HTFL pay a dividend?
No, Heartflow, Inc. does not currently pay a dividend.
How profitable is HTFL?
In FY2025, Heartflow, Inc. had a net margin of -66.3% and a return on equity of -38.8%.
What is the analyst price target for HTFL?
The average Wall-Street price target for Heartflow, Inc. is $37.00, about 24.0% above the recent price, from 7 analysts (consensus: strong buy).
Is HTFL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Heartflow, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.